Safety & side effects
Liraglutide has one of the longest safety records in the GLP-1 class, more than 16 years of use since its 2010 US appro…
A well-characterized profile, with real warnings
Liraglutide has one of the longest safety records in the GLP-1 class, more than 16 years of use since its 2010 US approval (only exenatide, approved in 2005, is older), so its side effects are unusually well mapped. Most are gastrointestinal and fade with titration, but the label also carries a boxed warning for thyroid tumors and warnings covering pancreatitis, gallbladder disease, kidney injury, severe gastrointestinal reactions, and pulmonary aspiration under anesthesia.
This unit separates the common-but-manageable from the rare-but-serious, walks the contraindications and interactions, and closes with an honest ceiling. The goal is a calibrated view: neither alarmist about a well-studied drug nor dismissive of genuine, labeled risks.